SI1165044T1 - High potency dihydroergotamine compositions - Google Patents

High potency dihydroergotamine compositions

Info

Publication number
SI1165044T1
SI1165044T1 SI200030460T SI200030460T SI1165044T1 SI 1165044 T1 SI1165044 T1 SI 1165044T1 SI 200030460 T SI200030460 T SI 200030460T SI 200030460 T SI200030460 T SI 200030460T SI 1165044 T1 SI1165044 T1 SI 1165044T1
Authority
SI
Slovenia
Prior art keywords
high potency
dihydroergotamine
compositions
present
dihydroergotamine compositions
Prior art date
Application number
SI200030460T
Other languages
English (en)
Slovenian (sl)
Inventor
John R. Plachetka
Donna Gilbert
Original Assignee
Pozen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pozen, Inc. filed Critical Pozen, Inc.
Publication of SI1165044T1 publication Critical patent/SI1165044T1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
SI200030460T 1999-03-26 2000-03-15 High potency dihydroergotamine compositions SI1165044T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12633399P 1999-03-26 1999-03-26
PCT/US2000/006657 WO2000057851A2 (en) 1999-03-26 2000-03-15 High potency dihydroergotamine compositions
EP00917926A EP1165044B1 (en) 1999-03-26 2000-03-15 High potency dihydroergotamine compositions

Publications (1)

Publication Number Publication Date
SI1165044T1 true SI1165044T1 (en) 2004-10-31

Family

ID=22424248

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030460T SI1165044T1 (en) 1999-03-26 2000-03-15 High potency dihydroergotamine compositions

Country Status (25)

Country Link
US (2) US6495535B1 (es)
EP (1) EP1165044B1 (es)
JP (1) JP2002540136A (es)
CN (1) CN1187039C (es)
AT (1) ATE269056T1 (es)
AU (2) AU763568B2 (es)
CA (1) CA2368587A1 (es)
CZ (1) CZ20013455A3 (es)
DE (1) DE60011589T2 (es)
DK (1) DK1165044T3 (es)
EA (1) EA004307B1 (es)
EE (1) EE200100500A (es)
ES (1) ES2222895T3 (es)
GE (1) GEP20053473B (es)
HK (1) HK1045463B (es)
HR (1) HRP20010780A2 (es)
HU (1) HUP0200641A3 (es)
IL (1) IL145550A0 (es)
MX (1) MXPA01009658A (es)
PL (1) PL354955A1 (es)
PT (1) PT1165044E (es)
SI (1) SI1165044T1 (es)
SK (1) SK13742001A3 (es)
UA (1) UA70357C2 (es)
WO (1) WO2000057851A2 (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01009658A (es) * 1999-03-26 2003-06-24 Pozen Inc Composiciones de dihidroergotamina de alta potencia.
WO2001003645A2 (en) 1999-07-12 2001-01-18 Capnia, Incorporated Methods and apparatus for relieving headaches, rhinitis and other common ailments
US20060172017A1 (en) 1999-11-08 2006-08-03 Capnia, Incorporated Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
US20070039615A1 (en) 1999-11-08 2007-02-22 Capnia, Incorporated Methods and apparatus for treating rhinitis
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20030008005A1 (en) * 2001-07-05 2003-01-09 R.T. Alamo Ventures, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
FR2837708B1 (fr) * 2002-04-02 2005-02-04 Schwarz Pharma Lab Utilisation de la 8'-hydroxydihydroergotamine pour la fabrication d'un medicament contre la migraine
CA2529528A1 (en) * 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US9265732B2 (en) * 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
MX2009008582A (es) 2007-02-11 2009-10-30 Map Pharmaceuticals Inc Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios.
DE102007014947B4 (de) * 2007-03-23 2010-05-27 Axxonis Pharma Ag Stabilisierte wässrige Lösungen von Ergolinverbindungen
JP2011511674A (ja) 2008-02-07 2011-04-14 ユニヴァーシティ オブ ワシントン 周方向エアロゾルデバイス
US20110082150A1 (en) * 2008-02-11 2011-04-07 Robert Owen Cook Headache pre-emption by dihydroergotamine treatment during headache Precursor events
EP2344139A1 (en) 2008-09-09 2011-07-20 AstraZeneca AB Method for delivering a pharmaceutical composition to patient in need thereof
US20110008432A1 (en) * 2009-06-25 2011-01-13 Pozen Inc. Method for Treating a Patient in Need of Aspirin Therapy
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
RS59483B1 (sr) * 2009-10-30 2019-12-31 Intratus Inc Postupci i kompozicije za neprekidno oslobađanje lekova
WO2012054831A2 (en) 2010-10-21 2012-04-26 Rtu Pharmaceuticals, Llc Ready to use ketorolac formulations
BR122021002471B8 (pt) 2011-03-03 2022-10-25 Impel Neuropharma Inc Dispositivo de distribuição de droga nasal
CN107376071B (zh) 2011-05-09 2021-07-09 英倍尔药业股份有限公司 用于将化合物递送到使用者的上部嗅觉区的喷嘴
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
AU2013361337A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. 8'-Hydroxy-Dihydroergotamine compounds and compositions
EP2991713B1 (en) 2013-04-28 2019-06-19 Impel Neuropharma Inc. Medical unit dose container
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
JP6753927B2 (ja) 2015-09-10 2020-09-09 インペル ニューロファーマ インコーポレイテッド 直列形経鼻送達デバイス
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN110621314A (zh) 2017-01-04 2019-12-27 艾克萨姆治疗公司 包含美洛昔康的药物组合物
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
JP6186533B1 (ja) * 2017-03-31 2017-08-23 ナガセ医薬品株式会社 マキサカルシトール含有水溶液製剤の製造方法
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
EP3713628A4 (en) 2017-11-21 2021-08-18 Impel Neuropharma Inc. INTRA-NASAL DEVICE WITH DIVER TUBE
CA3081680A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with inlet interface
CA3088942C (en) 2018-01-05 2023-01-03 Impel Neuropharma, Inc. Intranasal delivery of dihydroergotamine by precision olfactory device
JP2021509677A (ja) 2018-01-05 2021-04-01 インペル ニューロファーマ インコーポレイテッド 精密嗅覚装置によるオランザピンの鼻孔間送達
US11083712B1 (en) 2018-03-20 2021-08-10 Relevale, Inc. Low concentration delivery of an ergoline derivative for treatment of a headache
US11517548B2 (en) 2018-07-19 2022-12-06 Impel Pharmaceuticals Inc. Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease
US10532049B1 (en) 2018-08-27 2020-01-14 Pharmaceutical Industries Limited Parenteral unit dosage form of dihydroergotamine
EP3906017A4 (en) 2019-01-03 2022-12-28 Impel Pharmaceuticals Inc. NASAL DRUG DELIVERY DEVICE
US11878109B2 (en) 2019-05-17 2024-01-23 Impel Pharmaceuticals Inc. Single-use nasal delivery device
US11786512B2 (en) 2019-09-23 2023-10-17 Slayback Pharma Llc Stable pharmaceutical compositions of dihydroergotamine mesylate
JP2023507890A (ja) * 2019-12-23 2023-02-28 サイエンチュア, インコーポレイテッド メシル酸ジヒドロエルゴタミン製剤およびその治療的送達のための事前充填注射器
WO2022009248A1 (en) * 2020-07-07 2022-01-13 Jordan University Of Science And Technology A pharmaceutical composition for treating migraine headaches and a cosolvent method of preparation thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138565A (en) 1975-05-31 1979-02-06 Sandoz Ltd. Stable solutions and processes for their preparation
DE2735587A1 (de) 1977-08-06 1979-02-15 Sandoz Ag Stabile loesungen und verfahren zu deren herstellung
DE2554533C3 (de) 1975-12-04 1984-08-30 Sandoz-Patent-Gmbh, 7850 Loerrach Verwendung von Dihydroergotamin und Heparin
DE2555481C3 (de) 1975-12-10 1985-10-03 Sandoz-Patent-GmbH, 7850 Lörrach Herstellung stabiler Tropflösungen von hydrierten Ergotalkaloiden
DE2621906A1 (de) 1976-05-17 1977-12-01 Sandoz Ag Neue therapeutische mischung und verfahren zu deren herstellung
YU17780A (en) 1980-01-23 1984-10-31 Lek Tovarna Farmacevtskih Process for preparing a stable solution of ergot alkaloid derivatives
DE3136282A1 (de) 1981-09-12 1983-03-24 Hoechst Ag "verfahren zur stabilisierung photoinstabiler arzneistoffe sowie stabilisierte arzneizubereitungen"
US5169849A (en) * 1982-02-01 1992-12-08 Sandoz Ltd. Nasal pharmaceutical compositions
DE3227122A1 (de) 1982-07-20 1984-01-26 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Stabile loesungen von mutterkornalkaloiden
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
FR2663224B1 (fr) 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
GB9502879D0 (en) * 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
MXPA01009658A (es) * 1999-03-26 2003-06-24 Pozen Inc Composiciones de dihidroergotamina de alta potencia.

Also Published As

Publication number Publication date
HK1045463B (zh) 2005-05-13
PT1165044E (pt) 2004-10-29
JP2002540136A (ja) 2002-11-26
AU3882500A (en) 2000-10-16
US20030114476A1 (en) 2003-06-19
CN1347313A (zh) 2002-05-01
HUP0200641A2 (en) 2002-08-28
DK1165044T3 (da) 2004-10-25
GEP20053473B (en) 2005-03-25
HUP0200641A3 (en) 2002-09-30
US7060694B2 (en) 2006-06-13
SK13742001A3 (sk) 2002-02-05
CA2368587A1 (en) 2000-10-05
AU2003246345B2 (en) 2005-04-14
CZ20013455A3 (cs) 2003-02-12
ATE269056T1 (de) 2004-07-15
DE60011589D1 (de) 2004-07-22
ES2222895T3 (es) 2005-02-16
HK1045463A1 (en) 2002-11-29
PL354955A1 (en) 2004-03-22
EA200101005A1 (ru) 2002-02-28
EE200100500A (et) 2003-02-17
AU763568B2 (en) 2003-07-24
EA004307B1 (ru) 2004-02-26
MXPA01009658A (es) 2003-06-24
DE60011589T2 (de) 2004-11-25
CN1187039C (zh) 2005-02-02
UA70357C2 (uk) 2004-10-15
EP1165044A2 (en) 2002-01-02
HRP20010780A2 (en) 2002-12-31
US6495535B1 (en) 2002-12-17
IL145550A0 (en) 2002-06-30
AU2003246345A1 (en) 2003-10-09
EP1165044B1 (en) 2004-06-16
WO2000057851A2 (en) 2000-10-05
WO2000057851A3 (en) 2001-01-11

Similar Documents

Publication Publication Date Title
HK1045463A1 (en) High potency dihydroergotamine compositions.
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
YU63002A (sh) Formulacija male doze entekavira i upotreba
GEP20032925B (en) Benzothiepines Having Activity As Inhibitors of Ileal Bile Acid Transport and Taurocholate Uptake
MY118371A (en) Tetrahydrolipstatin containing compositions
LU91254I2 (fr) Daptomycine et ses dérivés pharmaceutiquement acceptables (cubicinr)
HK1054918A1 (en) Compounds and compositions for delivering active agents
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
MXPA05013340A (es) Composiciones y metodos para liberacion mucosal incrementada de la hormona del crecimiento.
MY117892A (en) Therapeutic compounds
GEP20022824B (en) Antipicornaviral Compounds, Pharmaceutical Compositions Containing the Same and Methods for Treatment
TW221378B (es)
BG106155A (en) Novel derivatives and analogues of galanthamin
ATE334590T1 (de) Anti-arrhythmische zusammensetzungen und behandlungsverfahren
HUT70531A (en) Arylmorpholine derivatives, pharmaceutical compositions containing them as active agent and process for preparing them
MX9805441A (es) Compuestos terapeuticos.
ITMI932189A1 (it) Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
EA199901055A1 (ru) Фармацевтическая композиция для лечения и/или профилактики деменции
EP1347754A4 (en) COMPOSITIONS FOR PREVENTION OF ADHESION
JO2296B1 (en) Substituted pyrolates
MXPA02012957A (es) Formulacion nueva.
IL153003A0 (en) Medicaments for treating colics
UA36093A (uk) Спосіб лікування хронічного бронхіту